DNA replication vulnerabilities render ovarian cancer cells sensitive to poly(ADP-ribose) glycohydrolase inhibitors

Research output: Contribution to journalArticlepeer-review

  • External authors:
  • Nisha Pillay
  • Samantha Littler
  • Camilla Coulson-Gilmer
  • Nourdine Bah
  • Anya Golder
  • Dominic James
  • Kate Smith
  • Allan Jordan
  • Robert D. Morgan
  • Donald Ogilvie

Abstract

Inhibitors of poly(ADP-ribose) polymerase (PARP) have demonstrated efficacy in women with BRCA-mutant ovarian cancer. However, because only 15-20% of cases harbour BRCA mutations, additional strategies are required. Here, we show that a subset of ovarian cancer cell lines and ex vivo models derived from patient biopsies are intrinsically sensitive to a first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor. Sensitivity is due to underlying DNA replication vulnerabilities that cause persistent fork stalling and replication catastrophe. PARG inhibition is synthetic lethal with DNA replication genes, allowing additional models to be sensitized by CHK1 inhibitors. Because PARG and PARP inhibitor sensitivity are mutually exclusive, our observations demonstrate that PARG inhibitors have therapeutic potential to complement PARP inhibitor strategies in the treatment of ovarian cancer.

Bibliographical metadata

Original languageEnglish
Pages (from-to)519-533
JournalCancer Cell|Cancer Cell
Volume35
Issue number3
Early online date18 Mar 2019
DOIs
Publication statusPublished - 2019

Related information

Researchers

View all